BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding BioCardia, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 13 | 1 | 12 | 0 |
| Shares | 124.8K | 411 | 245.4K | +121.0K (+97.2%) |
| Value | $272.2K | $896 | $623.8K | +$352.5K (+129.9%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held BioCardia, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Brown Advisory Inc | 35,538 | $90.3K | 0.00% |
| Commonwealth Equity Services, LLC | 15,583 | $40.0K | 0.00% |
Sold out (2)
Institutions that held BioCardia, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| JPMorgan Chase & Co | 899 | $1.96K |
| Tower Research Capital LLC (TRC) | 535 | $1.17K |
Not filed for Q1 2025 yet (1)
Institutions that held BioCardia, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Global Retirement Partners, LLC | 411 | $896 |